Stockscreener 앱 받기
29.34
3.35%
0.95
시간 외 거래:
29.34
Dyne Therapeutics Inc 주식(DYN)의 최신 뉴스
Dyne Therapeutics director Incerti Carlo sells $474,045 in stock - Investing.com
Dyne therapeutics director Jason Rhodes sells $25,884 in stock - Investing.com
Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Acquired by US Bancorp DE - Defense World
HC Wainwright Predicts Weaker Earnings for Dyne Therapeutics - MarketBeat
Chardan Capital Expects Lower Earnings for Dyne Therapeutics - MarketBeat
Dyne Therapeutics, Inc. (NASDAQ:DYN) Short Interest Up 9.1% in October - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Trading Down 7.1%Time to Sell? - MarketBeat
RA Capital Management, L.P. Expands Stake in Dyne Therapeutics I - GuruFocus.com
Janus Henderson Group PLC's Strategic Acquisition in Dyne Therap - GuruFocus.com
Dyne Therapeutics (NASDAQ:DYN) Shares Gap DownTime to Sell? - MarketBeat
Deep Track Capital, LP Reduces Stake in Dyne Therapeutics Inc - GuruFocus.com
RTW INVESTMENTS, LP Expands Stake in Dyne Therapeutics Inc - GuruFocus.com
Dyne Therapeutics Reveals Q3 Results and Trial Updates - TipRanks
Dyne Therapeutics (NASDAQ:DYN) Given Buy Rating at HC Wainwright - MarketBeat
FMR LLC Bolsters Position in Dyne Therapeutics Inc with Signific - GuruFocus.com
Dyne Therapeutics Inc Reports Q3 2024 EPS of -$0.96, Missing Est - GuruFocus.com
Dyne Therapeutics Inc (DYN) Quarterly 10-Q Report - Quartzy
Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Dyne Therapeutics' DMD Drug Shows Promise; $723.7M Cash Position Fuels Clinical Progress | DYN Stock News - StockTitan
We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely - Simply Wall St
Lisanti Capital Growth LLC Has $622,000 Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Dyne Therapeutics Inc. (DYN) Quarterly 10-Q Report - Quartzy
Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases (NASDAQ:DYN) - Seeking Alpha
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $50.60 Average Price Target from Brokerages - MarketBeat
Creative Planning Has $381,000 Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Dyne Therapeutics to Present at Three Major Healthcare Investor Conferences | DYN Stock News - StockTitan
Dyne Therapeutics Enters Oversold Territory (DYN) - Nasdaq
Vanguard Group Inc's Strategic Acquisition in Dyne Therapeutics Inc - GuruFocus.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - PR Newswire
How the (DYN) price action is used to our Advantage - Stock Traders Daily
Dyne Therapeutics (DYN) Stock Dips Amidst Financial Report Insig - GuruFocus.com
Dyne cut to neutral by J.P. Morgan on stock's outperformance (NASDAQ:DYN) - Seeking Alpha
Dyne Therapeutics (NASDAQ:DYN) Downgraded by JPMorgan Chase & Co. to "Neutral" - MarketBeat
Dyne Therapeutics director Kersten Dirk sells shares totaling $475,878 - Investing.com India
Dyne Therapeutics director Kersten Dirk sells shares totaling $475,878 By Investing.com - Investing.com South Africa
Dyne Therapeutics (DYN) Shares Plummet Amid Market Volatility - GuruFocus.com
Where are the Opportunities in (DYN) - Stock Traders Daily
Dyne Therapeutics director Kersten Dirk sells $1.29 million in stock By Investing.com - Investing.com Australia
Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Dirk Kersten Sells 23,671 Shares - MarketBeat
Dyne Therapeutics, Inc. (NASDAQ:DYN) Short Interest Update - MarketBeat
Daily Market Movement: Dyne Therapeutics Inc (DYN) Sees a 0.84 Increase, Closing at 33.59 - The Dwinnex
Dyne Therapeutics Inc (DYN) did well last session? - US Post News
Dyne Therapeutics Inc (DYN) gets rating Reiterated from Chardan Capital Markets - Knox Daily
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Dyne Therapeutics’ DYNE-302 normalizes muscular pathology in preclinical FSHD - BioWorld Online
Selling Buzz: Dyne Therapeutics Inc [DYN] Director Kersten Dirk sells 21,518 shares of the company - Knox Daily
Trend Tracker for (DYN) - Stock Traders Daily
Dyne Therapeutics showcases clinical data at World Muscle Society Congress - Investing.com
Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases - The Manila Times
Dyne Therapeutics Presents Data at World Muscle Society - GlobeNewswire
Dimensional Fund Advisors LP Sells 155,444 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Trading Up 3.3%Here's What Happened - MarketBeat
Did Dyne Therapeutics Inc (DYN) perform well in the last session? - US Post News
Market Insights: Dyne Therapeutics Inc (DYN)’s Notable Drop of -2.76, Closing at 31.68 - The Dwinnex
DYN (Dyne Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily
3.66%
1.11%
자본화:
|
볼륨(24시간):